HKSE - Delayed Quote HKD

Alphamab Oncology (9966.HK)

7.340

+0.170

+(2.37%)

At close: May 9 at 4:08:05 PM GMT+8

High Growth Tech Stocks to Watch in Asia May 2025

As global markets navigate through easing trade tensions and mixed economic signals, Asia's tech sector remains a focal point for investors seeking high growth opportunities. In this dynamic environment, identifying promising tech stocks involves evaluating companies that demonstrate resilience amid economic uncertainties and possess the potential to capitalize on technological advancements.

Simply Wall St. 4 days ago

9966.HK
+2.37%

1686.HK
Undiscovered Gems In Asia And 2 Other Small Caps With Strong Potential

As global markets navigate a complex landscape marked by easing trade tensions and mixed economic indicators, small-cap stocks in Asia present intriguing opportunities for investors seeking growth beyond the well-trodden paths. In this environment, identifying promising small-cap stocks involves looking for companies with strong fundamentals and the ability to adapt to shifting market dynamics.

Simply Wall St. 5 days ago

9966.HK
+2.37%
A Pivotal Phase II/III Clinical Study of Anti-HER2 Bispecific Antibody KN026 Have Met the Primary Endpoint of PFS at Interim Analysis

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that a phase II/III clinical trial of anti-HER2 bispecific antibody KN026 (Study ID: KN026-001) in combination with chemotherapy as second-line or above treatment of HER2-positive gastric cancer (GC) (including gastroesophageal junction cancer (GEJ)), has completed the first interim analysis and met the pre-specified primary endpoint of progression-free survival (PFS)

PR Newswire 9 days ago

9966.HK
+2.37%
Alphamab Oncology Presented Preclinical Data on Two Novel Bispecific ADCs at the 2025 AACR Annual Meeting

Alphamab Oncology (stock code: 9966.HK) announced that the preclinical data on two novel bispecific antibody-drug conjugates (ADCs) JSKN021 and JSKN022 were presented as posters at the 2025 American Association for Cancer Research (AACR) Annual Meeting, which is held in Chicago, USA, from April 25 to 30, 2025.

PR Newswire 10 days ago

9966.HK
+2.37%
Three Undiscovered Gems In Asia To Enhance Your Investment Portfolio

As global markets grapple with economic uncertainty and inflation concerns, Asian stocks have shown resilience amidst these challenges. In this environment, identifying stocks that offer potential growth opportunities requires a keen focus on companies with strong fundamentals and adaptability to shifting market conditions.

Simply Wall St. last month

CHDGF

9966.HK
+2.37%

2510.HK
Alphamab Oncology Reports Full Year 2024 Financial Results and Business Highlights

Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2024 and highlighted recent business progress.

PR Newswire last month

9966.HK
+2.37%
Anti-HER2 Biparatopic ADC JSKN003 Has Been Granted Breakthrough-Therapy Designation for the Treatment of PROC

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has been granted Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The designation is for the treatment of platinum-resistant recurrent epithelial ovarian cancer (PROC), primary peritoneal cancer, or fallopian tube cancer, not

PR Newswire last month

9966.HK
+2.37%
Exploring 3 High Growth Tech Stocks in Asia

As global markets face headwinds from trade policy uncertainties and inflation concerns, Asia's tech sector continues to capture attention, particularly as Chinese markets rally on stimulus hopes. In this environment, identifying high-growth tech stocks involves looking for companies that can navigate economic challenges while capitalizing on technological advancements and consumer demand in the region.

Simply Wall St. last month

XIACF

XIACY

9966.HK
+2.37%
First Patient Dosed in a Phase III Clinical Study of Anti-HER2 Biparatopic ADC JSKN003 for the Treatment of HER2-positive Breast Cancer

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-301) of anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003. The study aims to compare the efficacy and safety of JSKN003 versus trastuzumab emtansine (T-DM1) for the treatment of HER2-positive advanced breast cancer.

PR Newswire 2 months ago

9966.HK
+2.37%
Alphamab doses first subject in trial of JSKN003 for ovarian cancer

The trial is designed to assess the ADC’s efficacy against investigator-selected chemotherapy.

Clinical Trials Arena 2 months ago

^YH206
High Growth Tech Stocks To Watch In February 2025

As global markets grapple with tariff uncertainties and mixed economic signals, major indices such as the S&P 500 and Nasdaq Composite have shown modest declines, reflecting investor caution amid geopolitical tensions and fluctuating job growth figures. In this environment, identifying high-growth tech stocks requires a keen understanding of how companies can adapt to evolving trade policies and leverage technological innovation to maintain robust earnings growth despite broader market...

Simply Wall St. 2 months ago

9966.HK
+2.37%
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003. The study aims to compare the efficacy of JSKN003 versus investigator-selected chemotherapy for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

PR Newswire 2 months ago

9966.HK
+2.37%
Anti-HER2 Bispecific ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for the Treatment of HER2-positive Breast Cancer

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to initiate a Phase III clinical study (Study ID: JSKN003-301). The study aims to compare the efficacy and safety of JSKN003 versus trastuzumab emtansine (T-DM1) for the treatment of HER2

PR Newswire 3 months ago

9966.HK
+2.37%
High Growth Tech Stocks To Watch In January 2025

As we enter January 2025, global markets are grappling with inflation concerns and political uncertainties, leading to a decline in U.S. equities and underperformance of small-cap stocks, as highlighted by the Russell 2000's dip into correction territory. In this volatile environment, identifying high-growth tech stocks requires a focus on companies that demonstrate resilience through innovation and adaptability to shifting economic conditions.

Simply Wall St. 3 months ago

9966.HK
+2.37%
Alphamab Oncology Announced Anti-HER2 Bispecific ADC JSKN003 Received Approval from CDE to Initiate a Phase III Clinical Study for Ovarian Cancer

Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to initiate a Phase III clinical study (study number: JSKN003-306). The study aims to compare the efficacy of JSKN003 versus investigator-selected chemotherapy for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or

PR Newswire 4 months ago

9966.HK
+2.37%
IND Application for a Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 was Approved

Alphamab Oncology (stock code: 9966.HK) announced that a phase I/II clinical trial (Study ID: JSKN033-102) of JSKN033, a high-concentration subcutaneous co-formulation consisting of anti-HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 immune checkpoint inhibitor, has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This study has previously been included in the "Pilot Program for Optimizing the Review and Approval of Clinical T

PR Newswire 4 months ago

9966.HK
+2.37%
High Growth Tech Stocks To Watch In December 2024

As global markets navigate a landscape of rate cuts and mixed economic signals, the technology-heavy Nasdaq Composite has reached new heights, contrasting with broader declines in major stock indexes. In this environment, high-growth tech stocks stand out as potential opportunities for investors seeking innovation-driven growth, especially as growth stocks continue to outperform value counterparts amidst evolving monetary policies and market dynamics.

Simply Wall St. 4 months ago

NORDH.OL

9966.HK
+2.37%
Alphamab Oncology Presented the Phase II Clinical Data of KN046 in Combination with Axitinib for the Treatment of Advanced NSCLC at ESMO IO Congress 2024

Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from a phase II clinical study on PD-L1/CTLA-4 bispecific antibody KN046 in combination with axitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) were presented at the European Society for Medical Oncology Immuno-Oncology Congress 2024 (ESMO IO Congress 2024).

PR Newswire 4 months ago

9966.HK
+2.37%
High Growth Tech Stocks To Watch In November 2024

As global markets navigate the uncertainties surrounding the incoming Trump administration, with notable impacts on sectors such as financials and energy, investors are closely watching key indices like the S&P 500 and Nasdaq Composite which have seen significant fluctuations. In this environment of policy shifts and economic adjustments, identifying high-growth tech stocks requires a focus on companies with strong fundamentals and adaptability to regulatory changes.

Simply Wall St. 5 months ago

9966.HK
+2.37%
Late-Breaking Abstract! Alphamab Oncology Presented the Latest Clinical Data of Anti-HER2 bispecific ADC Subcutaneous Co-formulation JSKN033 at SITC 2024

Alphamab Oncology (stock code: 9966.HK) announced that the results of the first-in-human clinical study of JSKN033, a high-concentration subcutaneous co-formulation consisting of anti-HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 immune checkpoint inhibitor, were presented for the first time as a poster in the Late-Breaking Abstract (LBA) session at the 39th Annual Meeting of the Society for Immunotherapy of Cancer in 2024 (SITC 2024).

PR Newswire 5 months ago

9966.HK
+2.37%

Performance Overview

Return	9966.HK	HANG SENG INDEX (^HSI)
YTD	+109.71%	+14.00%
1-Year	+43.08%	+23.36%
3-Year	-1.61%	+14.33%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Alphamab Oncology (9966.HK)

High Growth Tech Stocks to Watch in Asia May 2025

Undiscovered Gems In Asia And 2 Other Small Caps With Strong Potential

A Pivotal Phase II/III Clinical Study of Anti-HER2 Bispecific Antibody KN026 Have Met the Primary Endpoint of PFS at Interim Analysis

Alphamab Oncology Presented Preclinical Data on Two Novel Bispecific ADCs at the 2025 AACR Annual Meeting

Three Undiscovered Gems In Asia To Enhance Your Investment Portfolio

Alphamab Oncology Reports Full Year 2024 Financial Results and Business Highlights

Anti-HER2 Biparatopic ADC JSKN003 Has Been Granted Breakthrough-Therapy Designation for the Treatment of PROC

Exploring 3 High Growth Tech Stocks in Asia

First Patient Dosed in a Phase III Clinical Study of Anti-HER2 Biparatopic ADC JSKN003 for the Treatment of HER2-positive Breast Cancer

Alphamab doses first subject in trial of JSKN003 for ovarian cancer

High Growth Tech Stocks To Watch In February 2025

Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003

Anti-HER2 Bispecific ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for the Treatment of HER2-positive Breast Cancer

High Growth Tech Stocks To Watch In January 2025

Alphamab Oncology Announced Anti-HER2 Bispecific ADC JSKN003 Received Approval from CDE to Initiate a Phase III Clinical Study for Ovarian Cancer

IND Application for a Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 was Approved

High Growth Tech Stocks To Watch In December 2024

Alphamab Oncology Presented the Phase II Clinical Data of KN046 in Combination with Axitinib for the Treatment of Advanced NSCLC at ESMO IO Congress 2024

High Growth Tech Stocks To Watch In November 2024

Late-Breaking Abstract! Alphamab Oncology Presented the Latest Clinical Data of Anti-HER2 bispecific ADC Subcutaneous Co-formulation JSKN033 at SITC 2024

Performance Overview